Canada should negotiate a fairer share of drug R&D costs – Financial Post Op-Ed

Big changes are afoot in the way patent drugs are priced in Canada. At present, Canada’s Patented Medicine Prices Review Board (PMPRB), a federal agency, is responsible for setting maximum prices for patented drugs (i.e., pharmaceuticals, biologics and vaccines). The agency has been criticized for failing to rein in prices, which are higher than in some peer countries. This criticism is unfair: the tools the PMPRB was given to regulate drug prices when it was established in 1987 have become less effective over time.

From: William B.P. Robson

To: Canadian voters

Date: September 21, 2021

Re: The Election’s Over and Canada’s Spending Bill is Coming Due

Former Prime Minister Kim Campbell got pilloried in 1993 for saying an election is no time to discuss serious issues. Yet in September 2021, her words ring true.

How Will Canadians Feel About Today’s Campaign Promises When the Bill Comes Due? – Globe and Mail Op-Ed

Former Prime Minister Kim Campbell got pilloried in 1993 for saying an election is no time to discuss serious issues. Yet in September 2021, her words ring true. Foreign policy? We all but ignore the rest of the world. Monetary policy? Not something to think about, even with inflation above 4 per cent. Fiscal policy? Almost no one is talking about whether, over time, we will be willing and able to finance all the goodies being added to the federal budget.

From: Aurelien Portuese

To: Canadians Concerned About Competition

Date: September 17, 2021

Re: Principles of Dynamic Antitrust

Charles DeLand on The Agenda – Who has the Best Climate Plan?

Ahead of the federal election, The Agenda looked at the various party platforms on climate change. The C.D. Howe Institute's Associate Director of Research Charles DeLand spoke to Steve Paikin alongside Mark Jaccard, Professor of Sustainable Energy and Director of the School of Resource and Environmental Management at Simon Fraser University; Sarah Petrevan, Policy Director at Clean Energy Canada; and the Globe and Mail's Adam Radwanski.

To: Canadians concerned about innovation

From: John Lester

Date: September 16, 2021

Re: Canada’s Support for R&D is Unbalanced. A Patent Box Would Help.

Election platforms for both major parties contain pledges to reform Canada’s support system for research and development.

That is good news, because there is much to improve. Canada provides too much R&D support to small firms, not enough for large firms and could do better on commercialization.

Business Investment in Canada Not Keeping Pace with Workforce or Competitors Abroad

Business Investment in Canada Not Keeping Pace with Workforce or Competitors Abroad

September 16, 2021 – Recent figures on Canada’s stock of capital and new investment prefigure lower incomes for Canadian workers, according to a new report released by the C.D. Howe Institute.

In “Declining Vital Signs: Canada’s Investment Crisis,” authors William B.P. Robson and Miles Wu examine Canada’s stock of business capital and new investment, comparing it to the United States and other Organisation for Economic Co-operation and Development (OECD) countries.